Helicos Biosciences (United States)

Helicos Biosciences (United States)

Helicos BioSciences Corporation was a publicly traded life science company headquartered in Cambridge, Massachusetts focused on genetic analysis technologies for the research, drug discovery and diagnostic markets. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Helicos Biosciences (United States), United States, covering academic research published from 2004 to 2024. Read More.


Open Access Percentage

67%


Total
Publications

97


Total Open
Publications

65


Total
Citations

11K


Open Access
Percentage

67%


Total
Publications

97


Total Open
Publications

65


Total
Citations

11K

Wikipedia

Website

download

Breakdown

6% 39% 22% 33%

Publisher Open

6%

Both

39%

Other Platform Open

22%

Closed

33%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

024681012141618202224Total Publications
200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

25%OA Journal

OA Journal 25%

11

Hybrid 30%

13

No Guarantees 45%

20

Other Platform Open

Domain 97%

57

Institution 19%

11

Public 7%

4

Preprint 0%

0

Other Internet 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
57
Europe PMC
Domain
41
Semantic Scholar
Public
4
Cold Spring Harbor Laboratory - Cold Spring Harbor Laboratory Institutional Repository
Institution
4
University of Oxford - Oxford Academic Notes & Queries
Institution
2
Massachusetts Institute of Technology - DSpace@MIT
Institution
2
American Medical Association - The Journal of the American Medical Association (JAMA) Network
Institution
2
Université de Lausanne - SERVAL
Institution
1
University of Toronto - TSpace
Institution
1
University of Geneva - Archive ouverte UNIGE
Institution
1
1 / 2

Data updated 13 February 2025

Share

Share

Share